John Clarke

John Clarke

Non-Executive Chairman and Chairman of Nomination Committee

Current roles: John Clarke became Chairman of Futura Medical plc in 2012. He is a member of the Nominations Committee and the Remuneration Committee. He is also the Non-Executive Chairman of Science in Sport plc and Kind Consumer Holdings Limited and a senior advisor to Helios Investment Partners LLP.

Past roles: Appointed President of GSK Consumer Healthcare in 2006, a position from which he stepped down in 2011. Under his leadership, GSK Consumer Healthcare became one of the fastest-growing companies in its industry. Non-executive Chairman of Quantum Pharma Plc.

Brings to the Board: Extensive experience of the healthcare sector, having worked at GSK for more than 35 years.

James Barder

James Barder

Chief Executive

Current roles: James Barder joined the Group as Chief Executive in 2001. He assists the Remuneration Committee and the Nominations Committee (but is not a member of and does not vote on either). He has overall responsibility for all activities of the Group, is a principal contact for shareholder and investor relations matters and leads commercial negotiations. He first became involved with the Group in 1997.

Past roles: Managing Director of Aon Capital Markets Limited and Non-Executive Director of Lorega Limited. James has predominantly worked in the field of insurance and finance including firms he founded.

Brings to the Board: Over 25 years of experience in setting up, managing and running companies.

Derek Martin

Derek Martin, BSc (Hons), ACA

Finance Director

Company Secretary

Current roles: Derek Martin joined the Board in 2008. He oversees the Group's finance function, its compliance procedures and is a principal contact for shareholder and investor relations matters.

Past roles: Senior financial roles in a diverse range of industries including retail, software, telecoms and advertising, media and sales promotion.

Brings to the Board: Over 25 years of experience in finance.

Ken James

Ken James

Executive Director and Head of R&D

Current roles: Ken James joined the Board in April 2016. In November 2016 he was appointed Head of R&D. He oversees the development, regulatory and manufacturing strategies for the company's existing pipeline and the evaluation of early stage pipeline opportunities. He is a member of the Nominations Committee, the Remuneration Committee and the Audit Committee.

Past roles: Senior Vice President of Research and Development for GlaxoSmithKline Worldwide Consumer Healthcare, having worked in the UK and the United States.

Brings to the Board: Over 40 years' experience in the research, development and commercialisation of consumer healthcare products.

Jonathan Freeman

Jonathan Freeman, BA (Hons), MBA

Senior Independent Non-Executive Director and

Chairman of Remuneration Committee and Audit Committee

Current roles: Jonathan Freeman joined the Board in 2003 and was appointed Senior Independent Non-Executive Director in November 2003. He chairs the Audit Committee and the Remuneration Committee and is also a member of the Nominations Committee. He is also an Executive Director of Braveheart Investment Group plc and a Director of PhotonStar LED Group plc.

Past roles: Director of Beeson Gregory, Chief Executive Officer of Syndicate Asset Management plc and a Director of Hume Securities plc.

Brings to the Board: Over 25 years of experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.